Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA 'Completely Reworks' Parts Of Gene Therapy Products Guideline

Executive Summary

The European Medicines Agency has revised several sections of its 2001 guidance on the development and evaluation of gene therapy medicinal products based on stakeholder feedback and to address issues in light of the experience gained with these products.

You may also be interested in...

Familiar Principles In Gene Therapy Guidance For Rare Diseases

Use of historical controls and alternative study designs are allowed, but randomized control trial is preferred.

EMA Close To Finalizing Gene Therapy Products Guidance; No Scope For Further Approximation To International Norms

The European Medicines Agency says there is no scope to harmonize further its guidance on gene therapy medicinal products with international norms as the main focus of the document is on fulfilling data requirements to support an EU marketing authorization application.

Roche’s Eye Drug Scores First UK Approval Under Access Consortium

The UK MHRA has approved its first drug under an international work-sharing initiative that also includes regulators from Australia, Canada, Singapore and Switzerland.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts